Cabot (CBT)
(Delayed Data from NYSE)
$91.93 USD
-0.76 (-0.82%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $91.83 -0.10 (-0.11%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
CBT 91.93 -0.76(-0.82%)
Will CBT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CBT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CBT
Here's Why Cabot (CBT) is a Strong Value Stock
Here's Why Cabot (CBT) is a Strong Value Stock
CBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Cabot (CBT) is a Top Value Stock for the Long-Term
Why Cabot (CBT) is a Top Value Stock for the Long-Term
Strength Seen in Compass (CMP): Can Its 13.3% Jump Turn into More Strength?
Other News for CBT
Housing starts for March 2024
FCM welcomes new federal plan to address the homelessness and housing crises in Canada
Cabot Corporation to Announce Second Quarter 2024 Operating Results
Lower housing starts forecast in 2024 before recovering over next two years
BioCorRx receives new patent for novel compound to treat pain, depression, and schizophrenia